Top 10 Allergy Vaccine Companies to Watch for Growth in 2025–2030

ResearchAndMarkets.com has identified ten key companies in the allergy vaccine sector expected to lead in growth and innovation from 2025 to 2030. The report details companies making significant advancements in immunotherapy and patient care.

ALK-Abelló A/S and Stallergenes Greer LLC are highlighted as frontrunners. ALK-Abelló focuses on recombinant allergen platforms and precision medicine, while Stallergenes Greer offers a broad portfolio of subcutaneous and sublingual immunotherapies. Both companies have expanded their global presence and invested heavily in research.

Other notable companies include Allergopharma GmbH & Co. KG, specializing in individualized vaccines and stringent quality control, and pharmaceutical giant Merck & Co., Inc., leveraging its advanced research capabilities and distribution network. DBV Technologies S.A. is recognized for its pioneering work in non-invasive delivery methods like epicutaneous immunotherapy.

The list also features Allergy Therapeutics plc, Laboratorios LETI, S.L., HAL Allergy B.V., Bencard Allergie GmbH, and Torii Pharmaceutical Co., Ltd. These firms contribute through rapid-onset immunotherapies, novel adjuvants, recombinant and traditional vaccines, and region-specific solutions. Many collaborate with academic institutions to drive product development.

These companies operate in a sector shaped by scientific breakthroughs, evolving patient needs, and adaptable supply chains. The report provides a competitive analysis of strategies, emerging trends, and forecasts through 2030.